TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00130598
Drug: NaCl 0.9% i.v. or NaBic 1.4% i.v. or NaBic 1.4% i.v. + NaBic p.o. (Nephrotrans®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group: preventive hydration with 154mEq/l saline at 1ml/kg per hour of 12 hours prior and after the procedure.~7h-sodium bicarbonate: before contrast 3ml/kg NaHCO3 166mEq/l for one hour, followed by NaHCO3 166mEq/l (1ml/kg per hour until 6h after contrast).~short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg) as a bolus 20 minutes before contrast; ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl non-sparkling mineral water at the start of the infusion. Ingestion of non-sparkling mineral water in the first 6 hours after contrast.
Study: NCT02574637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching Brazikumab IV infusion as per protocol specified dosing schedule.
Study: NCT00859703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 35 mg once a week for 24 months
Study: NCT00835614
Drug: CEFZIL® for Oral Suspension 250 mg/5mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 250 mg/5 mL, single-dose fasting
Study: NCT02517489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
Study: NCT03434769
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60mg/Kg on day -6
Study: NCT00006479
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006479
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006479
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00985439
Drug: Diclofenac Test (upper dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35-mg Single dose
Study: NCT00985439
Drug: Celecoxib 400 mg
Normalized name: celecoxib 400 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules 2 x 200 mg Single-dose
Study: NCT02581423
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive oral capecitabine, 1250 miligrams per meter-squared (mg/m\^2) twice daily, in 3-week treatment cycles for up to 8 cycles. Treatment will be administered for 2 weeks followed by 1 week of rest without medication.
Study: NCT00985439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules 2 Single-dose
Study: NCT02784808
Drug: Non-Biologic DMARDs
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive non-biologic DMARDs as per standard of care. The choice of specific non-biologic DMARD will be at the descretion of treating physician.
Study: NCT02071121
Drug: BIIB061
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB061 capsules for oral administration
Study: NCT02071121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB061 matching placebo capsules
Study: NCT01580618
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 60 ml normal saline twice a day for three days using the existing chest tube.
Study: NCT03919799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive substance
Study: NCT00382577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01433614
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1650 mg/m2 p.o. days 1-14 every 3 weeks study arm B
Study: NCT01031355
Drug: Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, single dose, 3 mg EV + 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
Study: NCT00088478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03951402
Drug: Placebo matching CG5503 PR tablet
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet to CG5503 PR tablet.
Study: NCT00465205
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral twice daily
Study: NCT03535116
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toradol is a type of brand name. We will be using the generic version.
Study: NCT01482884
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 sc injections of every 2 weeks for 12 weeks.
Study: NCT01234298
Drug: SPD489 High-Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPD489 50, 60, or 70 mg capsules taken once-daily for up to 26 weeks
Study: NCT01234298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule taken once-daily for up to 26 weeks
Study: NCT00539136
Drug: GSK561679 tablet or solution
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00439244
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5.0 mg in a ready-to-infuse plastic bottle with a total fill volume of 103 mL to allow an infusion of 100 mL total volume corresponding to 5 mg of zoledronic acid.
Study: NCT00439244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronic acid matched placebo as a 103 mL solution of sterile water (physiologic 0.9% normal saline) to allow an infusion of 100 mL total volume in a ready-to-infuse plastic bottle
Study: NCT00070174
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00070174
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02021240
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02888444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 0.5mg tablets taken twice daily
Study: NCT00018200
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low exposure (40-70 ng/mL), Middle exposure (70-130 ng/mL), High exposure (130-200 ng/mL)
Study: NCT00018200
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low exposure (200-399 ng/mL), Middle exposure (400-499 ng/mL), High exposure (500-700ng/mL)
Study: NCT00887978
Drug: UT-15C SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: treprostinil diolamine sustained release tablets
Study: NCT00887978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01188863
Drug: 300 mg LX4211 (150 mg tablets)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of two 150 mg tablets LX4211
Study: NCT01188863
Drug: 300 mg LX4211 (50 mg tablets)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of six 50 mg tablets LX4211
Study: NCT01188863
Drug: 300 mg LX4211 (liquid)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL)
Study: NCT02305056
Drug: C13 N15 Valine
Normalized name: SOR-C13
DrugBank: SOR-C13 (DB15366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C13 N15 Valine administration
Study: NCT03996252
Drug: Calcipotriene 0.005% Foam
Normalized name: CALCIPOTRIENE 0.005% FOAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of calcipotriene foam in conjunction with generic efudex cream to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
Study: NCT03996252
Drug: Efudex 5% Topical Cream
Normalized name: Efudex 5% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of generic efudex cream in conjunction with calcipotriene foam to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
Study: NCT01543698
Drug: LGX818
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01543698
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01543698
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02974166
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The medication was prescribed by the dentist as nonsteroidal anti-inflammatory drug if necessary.
Study: NCT00566371
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03119077
Drug: BAY1161116
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of BAY1161116; single dose administration; redosing of BAY1161116 at dose group 1 together with itraconazole; redosing of BAY1161116 at dose group 2 as liquid service formulation, redosing of BAY1161116 at dose group 3 together with food
Study: NCT03119077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of respective placebos; single dose administration; redosing of placebo at dose group 1 together with itraconazole; redosing of placebo at dose group 2 as liquid service formulation, redosing of placebo at dose group 3 together with food
Study: NCT04374032
Drug: The standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The usual therapeutically established protocol, for the treatment of patients with moderate to severe COVID-19 infection prescribed by The Agency for medicinal products and medical devices of Bosnia and Herzegovina
Study: NCT02264197
Drug: BIBX 245 CL - fed
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02824874
Drug: Duvie Tab. 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duvie Tab. 0.5mg\*1T/day for 5days, QD, PO
Study: NCT02824874
Drug: Duvie Tab. 0.5mg + Januvia Tab. 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duvie Tab. 0.5mg + Januvia Tab.100mg\*1T/day for 5 dyas, QD, PO
Study: NCT04090021
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use in a drug combination for H. pylori eradication
Study: NCT00943059
Drug: Cellulosum Mycrocryst
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.
Study: NCT01575769
Drug: RoActemra/Actemra (tocilizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 8 mg/kg every 4 weeks for 104 weeks
Study: NCT00006258
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006258
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03034356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01839851
Drug: Treatment with any inhaled corticosteroid
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of any inhaled corticosteroid (daily frequency and dose will be registered)
Study: NCT01839851
Drug: Treatment with any intranasal glucocorticoid
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of any inhaled intranasal glucocorticoid (daily dose and frequency will be registered)
Study: NCT03879707
Drug: Melatonin 5 mg
Normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin is known to induce sleep
Study: NCT03879707
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02557620
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin)once daily or once weekly.
Study: NCT03675880
Drug: TAB014
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAB014 of 1.25mg(0.05ml)、2.00mg(0.08ml)、2.50mg(0.10ml)
Study: NCT02499029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical looking placebo pills were administered each week.
Study: NCT04635943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo presentation will be an oral drop solution undistinguishable from ivermectin, but without this device pharmaceutical ingredient.
Study: NCT00429416
Drug: L-leucyl-L-leucine Methyl Ester (LLME)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of L-leucyl-L-leucine methyl ester (LLME) treated donor white blood cells
Study: NCT00823368
Drug: STX209
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00429416
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 1gm/m2 prior to HSCT infusion
Study: NCT02259868
Drug: BILR 355 BS /1B, current low dose formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02259868
Drug: BILR 355 BS /1B, current high dose formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02259868
Drug: BILR 355 BS - Suspension high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00643227
Drug: azithromycin SR
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single, 2.0 g oral dose of azithromycin sustained release (SR) by mouth once daily
Study: NCT00105469
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin ophthalmic solution; one topical drop to the infected eye or eyes four times daily at 4 to 6 hour intervals (first dose in the morning between 7 and 10am) for 5 days.
Study: NCT02720471
Drug: Locoregional anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: classical analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh
Study: NCT02720471
Drug: peroperative infiltration of local anesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: peroperative infiltration of local anesthetics
Study: NCT00621985
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects were given their baseline hydrocortisone regimen which was three times daily for 4 of the subjects and twice daily for one subject. Doses were given at 8 AM, 2 PM, and 8 PM. The 2 PM time point was skipped for the subject who received hydrocortisone twice daily. Doses ranged from 6.9 to 18.5 milligrams per meter squared per day and were based on each individual's baseline regimen.
Study: NCT03229278
Drug: Enzyme Inhibitor Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given trigriluzole PO
Study: NCT00630981
Drug: Pharmacological treatment (Quetiapine and/or Escitalopram)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine for psychotic symptoms/Escitalopram if depressive disorders
Study: NCT00653744
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04467060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, fasting oral administration
Study: NCT00574847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
Study: NCT00691015
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02161367
Drug: Oral Suspending Vehicle
Normalized name: Base PCCA-PLUS Oral Suspending Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORA-Plus is an aqueous-based vehicle.~Identical to the test drug formulation except for being pharmacologically inert. 160mg Ora-Plus orally, 4 times a day for the first five postoperative days
Study: NCT03292588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered every 4 weeks by subcutaneous injection at a dose of:~* 100 mg for participants ≥12 years of age and~* 40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study.
Study: NCT01581814
Drug: Yasmin;
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1pill/day for cycles of 28 days (21 pills followed by 7 no-pill days)
Study: NCT01468012
Drug: levodopa carbidopa and entacapone (LCE)
Normalized name: carbidopa / entacapone / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg/100mg/200mg, twice daily
Study: NCT01468012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo for LCE condition dosed twice daily
Study: NCT01525537
Drug: administration of sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microgram sufentanil were given when SPI above 50 for more then 20 sec
Study: NCT01525537
Drug: sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sufentanil was given at standard practise
Study: NCT04506021
Drug: Bicarbonate Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the choices of the patients' immediate family members, patients will be divided into Bicarbonate Ringer's Solution. no Intervention.
Study: NCT00436683
Drug: Fermagate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated tablet 500mg
Study: NCT00834561
Drug: Lamictal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Tablet
Study: NCT02817191
Drug: Hylo-Comod eye drop
Normalized name: Hylocereus undatus fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were administrated Hylo-Comod eye drop four times a day after Phaco+IOL
Study: NCT02817191
Drug: Tears Naturale Forte eye drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were administrated Tears Naturale Forte eye drop four times a day after Phaco+IOL
Study: NCT01087398
Drug: Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For sibling full match:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2
Study: NCT01087398
Drug: Cyclosporin, Methotrexate (GVHD prophylaxis)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in PBSCT and +11 in BMT or UCBT) then 9 mg/kg/day po~* 10 mg/m\^2 iv day +1 then 6 mg/m\^ iv day +3 and +6 (Not for UCBT)
Study: NCT01167894
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
Study: NCT02680379
Drug: Minocycline, then Minocycline/Lovastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants of this group will take 1 tablet of minocycline 50mg daily for 4 weeks, minocycline 100mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40mg for the following 12 weeks.
Study: NCT02680379
Drug: Lovastatin, then Minocycline/Lovastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants of this group will take 1 tablet of lovastatin 20 mg daily for 4 weeks, lovastatin 40 mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40 mg for the following 12 weeks.
Study: NCT02568046
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard FOLFIRI regimen consists of Irinotecan (180 mg/m\^2 IV, infused over 60-90 minutes) concurrently with Folinic Acid (400 mg/m\^2 IV, infused over 120 minutes) followed by 5-FU (400 mg/m\^2 IV bolus, then 2400 mg/m\^2 infused over 46 hours).
Study: NCT00471068
Drug: Placebo (Timolol Vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travatan group: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
Study: NCT02998593
Drug: Bahman capsules
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Use of Bahman capsules for 3 months by patients.
Study: NCT02998593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral use of placebo capsules by patients for 3 months.
Study: NCT01675960
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is a glycerin-based clear solution that is flavored similarly to the commercial product. The placebo will be given orally or through a gastrointestinal tube.
Study: NCT03138876
Drug: Anti-seizure medication
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients may be treated for NCSE or seizures based on EEG cap findings, if the findings are clear to an attending EEG reviewer. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
Study: NCT02599129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ￼subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.
Study: NCT01698645
Drug: PecFent® (fentanyl) nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01501786
Drug: Ket10
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol 6.4 mg/kg/h ketamine 10 microg/kg/min
Study: NCT01501786
Drug: Ket20
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol 4.8 mg/kg/h ketamine 20 microg/kg/min
Study: NCT01228760
Drug: ASG-5ME
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT00070278
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00084721
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no